Gilead Sciences, Inc.
FXR (NR1H4) MODULATING COMPOUNDS

Last updated:

Abstract:

The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Status:
Application
Type:

Utility

Filling date:

10 May 2019

Issue date:

17 Oct 2019